Limited-Stage SCLC: Unmet Needs and Emerging Biomarkers

In "Limited-Stage SCLC: Unmet Needs and Emerging Biomarkers," the panel steps back to take stock of what still needs to improve before moving on to extensive-stage disease.

Before pivoting to extensive-stage disease, the panel pauses to take stock of what remains unresolved in limited-stage small cell lung cancer, even with consolidation immunotherapy now part of standard care. The most fundamental unmet need is recurrence itself: most patients still relapse, meaning cure rates have not risen as far as hoped, and higher cure rates remain the ultimate goal. The panel expresses particular enthusiasm for DLL3-targeted T-cell engagers as a potential next step toward improving on that number, alongside the broader hope that emerging systemic agents developed for other settings will eventually move into limited-stage treatment in a biomarker-driven rather than one-size-fits-all fashion.

Screening and earlier detection resurface as a second unmet need, with the panel noting that the roughly 30% of patients who present with limited-stage disease represents a number worth pushing higher through continued screening efforts, since earlier detection can produce better outcomes. Circulating tumor DNA is raised as a promising tool for individualizing treatment duration, questioning whether the fixed two-year course of durvalumab used in ADRIATIC is truly optimal for every patient, or whether some patients could be treated for shorter or longer periods based on molecular monitoring.

The episode closes by placing this moment in historical context, comparing the current trajectory in small cell lung cancer to the transformation seen in non-small cell lung cancer a decade earlier. With antibody-drug conjugates, bispecific agents, and studies like TERLA on the horizon, the panel conveys genuine optimism that today's unmet needs represent the next wave of progress rather than a plateau, even as they acknowledge how much work remains before higher cure rates become routine.

Our next episode, "Extensive-Stage SCLC: The Case for Adding Immunotherapy," pivots the conversation to extensive-stage disease and the case for immunotherapy there.